AMED3001 Cancer
The Complete Exam Bible · S1 2027Cancer
AMED3001 Cancer is the University of Sydney's third-year, 6-credit-point unit in the School of Medical Sciences, co-taught at Westmead with the advanced stream AMED3901, and it is built around three modules: Cancer Facts & Diagnosis, Carcinogenesis, and Cancer Treatment. The unit works from what cancer is — the hallmarks of cancer, tumour structure and metastasis, histopathology, grading and staging — through why it happens — carcinogens, oncogenes and tumour-suppressor genes, epigenetics, driver pathways and clonal evolution — to how it is treated — conventional chemo- and radiotherapy, targeted and cell therapy, immunotherapy and precision medicine. It is a mechanism-and-reasoning subject: the marks reward naming the right pathway, stating a mechanism in the correct direction, and interpreting real data. AMED3001 is assessed through Canvas as continuous coursework — a Module 1 practical report (10%), a Module 2 practical assignment (10%), a mid-semester quiz (20%), a 3-minute student pitch (4%) and a Module 3 practical report (6%) — capped by a comprehensive final examination worth 50% (the weight is set in the Canvas unit outline, not the public handbook — confirm on Canvas). Per the unit coordinator the final is MCQ plus short-answer with marks varying per question, and everything from lectures and workshops is examinable, including data-interpretation skills — reading gene-expression heatmaps and annotating gene sequences. That structure rewards steady work across the semester and through STUVAC, and the AMED3001 result feeds the Weighted Average Mark (WAM) that later units build on. (AMED3901 Cancer Advanced shares the same 50% exam but replaces the smaller AMED3001 tasks with a 20% case-study presentation.)
What AMED3001 covers
AMED3001 Cancer is taught across three modules — Cancer Facts & Diagnosis, Carcinogenesis, and Cancer Treatment — and this eleven-chapter map follows that schedule from the hallmarks of cancer through to precision medicine. The University of Sydney assesses AMED3001 through continuous coursework (practical reports, a Module-2 poster assignment, a mid-semester quiz and a 3-minute pitch) plus a comprehensive final exam worth 50% (confirm on Canvas), whose MCQ and short-answer questions span every lecture and workshop and, the coordinator confirms, data-interpretation skills — reading gene-expression heatmaps and annotating gene sequences. Use it to see how each week's mechanism builds toward that final.
How AMED3001 is assessed
| Component | Weight | Format |
|---|---|---|
| Final Exam | 50% | USyd S1 exam period; MCQ + short-answer, marks vary per question; lectures + workshops + data-interpretation (heatmaps, gene-sequence annotation) examinable |
| Mid-Semester Quiz | 20% | ~Week 9 |
| Module 1 Practical Report | 10% | ~Week 4-5 (cancer pathology practical) |
| Module 2 Practical Assignment | 10% | ~Week 8 |
| Module 3 Practical Report | 6% | ~Week 13 (comet-assay / DNA-damage practical) |
| Student Pitch | 4% | ~Week 12 (precision-medicine pitch) |
| Module 1 Quiz | 0% (formative) | ~Week 4 |
Synthetic lethality: why a PARP inhibitor works in BRCA1-mutant triple-negative breast cancer
- +1BRCA1 is a tumour-suppressor gene essential for repairing DNA double-strand breaks by homologous recombination (HR), working with BRCA2, PALB2 and RAD51.
- +1In the tumour, BRCA1 function is lost, so the cancer cells are HR-deficient and cannot accurately repair double-strand breaks; normal cells still carry a working BRCA1 allele and remain HR-competent.
- +1PARP1 normally repairs single-strand breaks (base-excision repair). A PARP inhibitor leaves single-strand breaks unrepaired, and at the replication fork these collapse into double-strand breaks.
- +1Synthetic lethality: in the HR-deficient tumour cell those double-strand breaks cannot be repaired → genomic catastrophe → apoptosis, whereas the HR-competent normal cell repairs them and survives — two individually survivable defects are lethal only together.
- +1Personalised rationale: match therapy to the molecular profile — surgery to remove the primary, then chemotherapy plus a PARP inhibitor exploiting the BRCA1 defect, with BRCA status confirmed by hereditary (germline) genetic testing.
Key terms
- Neoplasm (benign vs malignant)
- An abnormal mass of tissue arising when cells proliferate more than they should or fail to die. Benign = does not invade or spread; malignant (cancer) = invades local tissue and can spread via blood and lymph.
- Metastasis
- The spread of cancer cells from the primary tumour to a distant site to form secondary tumours. More than 90% of cancer deaths are due to metastasis.
- Oncogene
- A gain-of-function mutant of a normal proto-oncogene that drives proliferation; a single activating hit is sufficient. Examples: RAS, MYC, EGFR, HER2, BRAF.
- Tumour-suppressor gene (TSG)
- A gene whose normal product restrains division or triggers repair/death; cancer arises through loss of function, and both alleles must be inactivated (the two-hit hypothesis). Examples: p53, Rb, APC, BRCA1/2.
- Grade vs Stage
- Grade = intrinsic aggressiveness read microscopically (differentiation, growth pattern, mitotic count). Stage = the amount and spread of cancer in the body, scored by the TNM system (Tumour, Nodes, Metastasis).
- Hallmarks of cancer
- The organising framework (Hanahan & Weinberg) of the capabilities a tumour acquires — sustained proliferation, evading growth suppressors, resisting death, replicative immortality, angiogenesis and invasion/metastasis, plus deregulated metabolism and immune evasion, enabled by genome instability and tumour-promoting inflammation.
AMED3001 FAQ
Is AMED3001 hard?
It is broad rather than mathematically hard — there are no calculations, but the unit runs from cell biology and histopathology through molecular genetics to therapeutics, so the challenge is keeping a large web of mechanisms and their directions straight (which gene is a tumour suppressor, which pathway a driver activates, which therapy hits which target). Students who revise the recurring mechanisms weekly rather than cramming through STUVAC, and who practise the data-interpretation skills the coordinator flags, tend to find it manageable. The mid-semester quiz (20%) and continuous practicals mean marks accumulate all semester, and the result feeds your Weighted Average Mark (WAM).
Can AI help me with AMED3001?
Yes — Sia is an AI tutor trained on how AMED3001 is actually taught and assessed. It explains a mechanism step by step — how HPV E6/E7 disable p53 and pRb, why a PARP inhibitor is synthetically lethal in a BRCA-mutant cell, or how to read a gene-expression heatmap — and checks your reasoning as you work. It does not do graded assessment for you, and University of Sydney academic-integrity rules apply. Use it to understand the method and rehearse, then confirm assessment details on Canvas and the unit outline.
Where can I find past exam papers/practice for AMED3001?
Start on Canvas, where the unit posts its official material, and search the University of Sydney Library past-exam-paper collection; your lecture and workshop concepts plus the practical questions are the closest guide to the final's style, since the coordinator says the papers you analysed are not examined in detail (only the underlying concepts and the data-interpretation skill). This guide also includes a re-authored practice exam that mirrors the final's MCQ-plus-short-answer shape with fresh scenarios, and you can ask Sia to build extra practice in the same style and explain each step. Treat any third-party ‘model answers’ with caution.
Does AMED3001 have a hurdle, and how is it assessed?
No hurdle is stated in the available unit materials — but absence of a stated hurdle is not the same as a confirmed ‘no hurdle’, so check the current rules on Canvas and the unit outline; do not assume either way. Assessment is continuous: a Module 1 practical report (10%), a Module 2 practical assignment (10%), a mid-semester quiz (20%), a 3-minute pitch (4%) and a Module 3 practical report (6%), plus the final exam worth 50% (the weight is set in the Canvas outline, not the public handbook — confirm on Canvas). Grade bands are the standard USyd HD/D/CR/P.
What is examined in the AMED3001 final?
Per the unit coordinator the final is MCQ plus short-answer (up to a short paragraph) with marks varying per question, and everything from the lectures and workshops is examinable. Crucially, data-interpretation is examinable — reading gene-expression heatmaps and annotating gene sequences — so practise those alongside the mechanisms. The research papers you analysed and the databases you explored are not examined in detail, only the underlying lecture concepts. Exam duration, open-versus-closed-book status and the number of questions are not published in the unit materials — confirm them on Canvas and the exam timetable.
How to study for the exam
Treat AMED3001 as three connected stories — what cancer is, why it happens, and how it is treated — and revise the recurring mechanisms weekly rather than banking on a STUVAC cram, because the mid-semester quiz (20%) and the practicals spread the marks across the whole semester. For each topic, be able to state the mechanism in the correct direction (which gene is lost versus activated, which pathway a driver switches on, whether a therapy is an agonist or an inhibitor) and give one worked example — a driver mutation, a therapy mechanism, a screening decision. Because the coordinator confirms data-interpretation is examinable, practise reading gene-expression heatmaps (rows, columns, red/blue Row Z-score, clustering), volcano plots and gene-sequence annotations until they are automatic. Keep the whole unit warm for the comprehensive 50% final rather than deep-diving one module. When a mechanism won't click, ask Sia to re-explain that single step a different way and to set you a fresh practice question in the same style — it teaches the method and checks your reasoning, and it never substitutes for your own graded work. Confirm the exam date, room and open/closed-book status on Canvas and the University of Sydney exam timetable.
Your AI Biology tutor for AMED3001
Stuck on a hard AMED3001 question? Sia is AskSia’s AI Biology tutor — ask any AMED3001 Cancer question and get a clear, step-by-step explanation grounded in how the course is actually taught and assessed. Read this whole study guide free, then take your hardest questions to Sia.
